Sanofi Sa · EURONEXT:SAN
Sanofi Sa — BofA-ML Healthcare Conference 2019
8 slides from Sanofi Sa's conference presentation, Sep 19, 2019
Slide 1: BofA-ML Healthcare Conference
BofA-ML Healthcare Conference John Reed Executive Vice President, Global Head of R&D September 19, 2019
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under
Slide 3: Next chapter in the evolution of Sanofi R&D
Next chapter in the evolution of Sanofi R&D Vision Strategy Long-term objectives(1) • An industry innovation leader • Allocate resources to priority • 80% first or best in class bringing transformative therapeutic areas • 70% biologics solutions to patients • Leverage multiple therapeutic • 70% inte
Slide 4: Increased research focus on Specialty Care and Vaccines while rigorously prioritizing development spend
Increased research focus on Specialty Care and Vaccines while rigorously prioritizing our development spend Evolution of pipeline projects Research(1) Development(2) 83 122 70 109 20 13 35 Primary Care 67 Specialty Care 94 44 Vaccines 65 13 12 9 8 Dec 2017 July 2019 Dec 2017 July 2019 (1) Number of
Slide 5: Significant progress made on executing our R&D strategy in H1 2019
Significant progress made on executing our R&D strategy in H1 2019 • Announced discontinuation of 13 development and 32 research projects • 95% of development projects now in specialty care and vaccines Prioritization • Refocus of CV and diabetes research(1,2) • Restructured Regeneron IO, Alnylam, a
Slide 6: Majority of NMEs are wholly-owned and expected to result in improved Corporate profitability
Majority of NMEs are wholly-owned and expected to result in improved Corporate profitability Initial Submission NME Mechanism of Action Indication Timing (2) isatuximab anti-CD38 mAb 3L RRMM (ICARIA) 2019 fitusiran(1) RNAi therapeutic targeting anti-thrombin Hemophilia A & B 2020 Sutimlimab(3) anti-
Slide 7: Several potential approvals for new drugs and additional indications over next 12 months
Several potential approvals for new drugs and additional indications over next 12 months 2019 2020 Q3 Q4 Q1 Q2 Fluzone® QIV HD for ≥ 65-years old age group (U.S.) Dupilimab®(2) in Chronic Rhinosinusitis with Nasal Polyps (EU) Potential Isatuximab in 3L Relapsed-Refractory Multiple Myeloma (U.S. and
Slide 8: R&D momentum driven by execution on strategy and positive data read-outs
R&D momentum driven by execution on strategy and positive data read-outs Accelerating transformation of R&D with shifting focus to specialty care and vaccines Building capabilities in digital platforms, gene therapy and biologics Positive data on priority programs in Rare Blood Disorder, Oncology, a